Sumitomo Mitsui Trust Group Inc. Acquires 22,108 Shares of Solventum Corporation $SOLV

Sumitomo Mitsui Trust Group Inc. lifted its holdings in Solventum Corporation (NYSE:SOLV) by 7.4% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 321,150 shares of the company’s stock after acquiring an additional 22,108 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Solventum were worth $20,971,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of SOLV. Assetmark Inc. raised its stake in Solventum by 21.4% in the 4th quarter. Assetmark Inc. now owns 725 shares of the company’s stock worth $57,000 after purchasing an additional 128 shares in the last quarter. Allworth Financial LP grew its position in shares of Solventum by 2.8% during the 3rd quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock worth $350,000 after purchasing an additional 129 shares in the last quarter. Hilltop National Bank increased its holdings in shares of Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after purchasing an additional 129 shares during the period. CIBC Private Wealth Group LLC increased its holdings in shares of Solventum by 0.5% during the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock worth $1,804,000 after purchasing an additional 134 shares during the period. Finally, BOKF NA raised its position in shares of Solventum by 6.9% in the third quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after buying an additional 141 shares in the last quarter.

Solventum Stock Performance

Shares of NYSE:SOLV opened at $77.48 on Tuesday. Solventum Corporation has a 1 year low of $62.38 and a 1 year high of $88.20. The stock has a market capitalization of $13.42 billion, a price-to-earnings ratio of 9.50, a price-to-earnings-growth ratio of 1.18 and a beta of 0.66. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The company’s 50 day simple moving average is $76.44 and its 200 day simple moving average is $74.26.

Solventum (NYSE:SOLV) last issued its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter last year, the business posted $1.34 EPS. The company’s revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, research analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on SOLV shares. Piper Sandler cut their price target on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. KeyCorp lifted their price objective on Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. UBS Group downgraded Solventum from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a research report on Thursday, May 14th. Wedbush started coverage on Solventum in a report on Friday, May 15th. They set an “outperform” rating and a $94.00 target price on the stock. Finally, Weiss Ratings cut Solventum from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, June 26th. Seven analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Solventum presently has a consensus rating of “Hold” and a consensus target price of $83.67.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.